Taiwan Advanced Nanotech Dividend Coverage

What does Taiwan Advanced Nanotech do? Taiwan Advanced Nanotech, Inc. generates revenue through the sale of nucleic acid purification products, including SLA series, Maelstrom series, and LH series instruments designed for DNA/RNA extraction. The company also sells specialized reagents such as virus nucleic acid extraction reagent 665 series, blood nucleic acid extraction reagent 611/61E series, and tissue nucleic acid extraction reagent 6T2/6K2 series. These products are marketed to customers in Taiwan, South Korea, and China, with sales primarily focused on laboratory and medical applications requiring nucleic acid processing. The company's product portfolio targets research institutions, diagnostic laboratories, and healthcare facilities seeking efficient nucleic acid extraction solutions. By offering a range of instruments and reagents tailored to specific extraction needs, Taiwan Advanced Nanotech addresses key segments in the biotechnology and medical diagnostics markets. Sales are distributed across Taiwan, South Korea, and China, reflecting the company's regional market focus. Revenue streams are derived from direct sales of instruments and reagents to end-users in the biotech and healthcare sectors. The SLA, Maelstrom, and LH series instruments serve as core revenue drivers, complemented by recurring reagent sales for ongoing laboratory operations. This dual-product approach ensures steady income from both capital equipment and consumable supplies. Taiwan Advanced Nanotech is one of the most popular companies on Eulerpool.